Loading...
Docoh

Bio-Path (BPTH)

News

From Benzinga Pro
10 Biggest Price Target Changes For Thursday
19 May 22
Penny Stocks, Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
Telsey Advisory Group cut the price target for Bath & Body Works, Inc. (NYSE: BBWI) from $70 to $60. Bath & Body Works shares fell 6.9% to $40.00 in pre-market trading.
HC Wainwright & Co. Maintains Buy on Bio-Path Holdings, Lowers Price Target to $9
19 May 22
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Yi Chen maintains Bio-Path Holdings (NASDAQ:BPTH) with a Buy and lowers the price target from $12 to $9.
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
17 May 22
Biotech, Earnings, Large Cap, News, Penny Stocks, Health Care, Small Cap, FDA, Legal, Management, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Bio-Path Holdings: Q1 Earnings Insights
17 May 22
Earnings, News
Bio-Path Holdings (NASDAQ:BPTH) reported its Q1 earnings results on Tuesday, May 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Bio-Path Holdings Q1 EPS $(0.47) Misses $(0.45) Estimate
17 May 22
Earnings, News
Bio-Path Holdings (NASDAQ:BPTH) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.45) by 4.44 percent. This is a 9.3 percent decrease over losses of $(0.43) per share from
Earnings Scheduled For May 17, 2022
17 May 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • On Holding (NYSE:ONON) is likely to report earnings for its first quarter.
A Preview Of Bio-Path Holdings's Earnings
16 May 22
Earnings
Bio-Path Holdings (NASDAQ:BPTH) is set to give its latest quarterly earnings report on Tuesday, 2022-05-17. Here's what investors need to know before the announcement. Analysts estimate that Bio-Path Holdings will report an earnings per share (EPS) of $-0.45.
Stocks That Hit 52-Week Lows On Friday
22 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 431 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Monday
18 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Monday, 466 companies hit new 52-week lows.
12 Health Care Stocks Moving In Wednesday's Intraday Session
13 Apr 22
Movers
Gainers
Why Bio-Path Holdings Shares Are Rising After Hours
12 Apr 22
Biotech, News, Penny Stocks, Movers, Trading Ideas, General
Bio-Path Holdings Inc (NASDAQ: BPTH) shares are trading higher in Tuesday's after-hours session following the company's BP1003 data presentation at the 2022 American Association for Cancer Research Annual Meeting.
Bio-Path Holdings Presents BP1003 Data At 2022 American Association For Cancer Research Annual Meeting
12 Apr 22
Biotech, News, FDA, Events, General
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today
The Daily Biotech Pulse: Valneva Gains On COVID Shot Regulatory Update, Lucira Health And Clearside Jump On Earnings, BeiGene Drug Snags Approval In China
11 Mar 22
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours.
Bio-Path Holdings: Q4 Earnings Insights
11 Mar 22
Earnings, News
Bio-Path Holdings (NASDAQ:BPTH) reported its Q4 earnings results on Friday, March 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Bio-Path Holdings FY21 Net Loss $1.55; Had Cash Of $23.8M As Of Dec. 31
11 Mar 22
Earnings, News
The Company reported a net loss of $10.4 million, or $1.55 per share, for the year ended December 31, 2021, compared to a net loss of $10.9 million, or $2.83 per share, for the year ended
Earnings Scheduled For March 11, 2022
11 Mar 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • The Real Good Food (NASDAQ:RGF) is estimated to report quarterly loss at $0.19 per share on revenue of $25.29 million.
Earnings Preview: Bio-Path Holdings
10 Mar 22
Earnings
Bio-Path Holdings (NASDAQ:BPTH) is set to give its latest quarterly earnings report on Friday, 2022-03-11. Here's what investors need to know before the announcement. Analysts estimate that Bio-Path Holdings will report an earnings per share (EPS) of $-0.32.

Press releases

From Benzinga Pro
Bio-Path Holdings Reports First Quarter 2022 Financial Results
17 May 22
Earnings, Press Releases
HOUSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of
Bio-Path Holdings Presents BP1003 Data at 2022 American Association for Cancer Research Annual Meeting
12 Apr 22
News, Health Care, Press Releases
HOUSTON, April 12, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of
Bio-Path Holdings Reports Full Year 2021 Financial Results
11 Mar 22
Earnings, Press Releases
HOUSTON, March 11, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio
Bio-Path Holdings to Present at the 2022 American Association for Cancer Research Annual Meeting
8 Mar 22
News, Press Releases
HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a
Bio-Path Holdings to Announce Full Year 2021 Financial Results on March 11, 2022
4 Mar 22
News, Press Releases
HOUSTON, March 04, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of